# A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma

> **NCT05183139** · PHASE4 · WITHDRAWN · sponsor: **Takeda**

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Ixazomib
- **DRUG:** Pomalidomide
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT05183139
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-06-30
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business decision (no enrollment)
- **Last updated:** 2022-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05183139

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05183139, "A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05183139. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*